推特 TWTR 深 沪
已收盘 11-16 16:00:00 美东时间
53.70
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 53.70
- 总市值 4108.05万
- 52周最高 54.57
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 31.30
- 委 比 0.00%
- 总股本 0.01亿
- 历史最高 80.75
- 量 比 0
- 振 幅 0.00%
- 历史最低 13.725
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SA Asks: What are the most overvalued tech stocks right now?
What are the most overvalued tech stocks right now? Seeking Alpha analysts Jonathan Weber and Bashar Issa weigh in. Jonathan Weber: I see Tesla (TSLA), if you count it as a tech stock, as widely overv...
05-09 23:00
被指人为压低股价，法官拒绝草率批准马斯克与SEC的和解协议：5月13日庭审见
据路透社5月9日报道，美国联邦法官周五拒绝迅速批准美国证券交易委员会（SEC）与特斯拉（TSLA.US）CEO马斯克（Elon Musk）就其购买推特（Twi...
05-09 14:08
Precipio Announces Q1-2026 Shareholder Update Call
Precipio, Inc. (NASDAQ: PRPO) will host its Q1-2026 shareholder update call on May 18, 2026, at 5:00 PM ET. The call will feature remarks on the company’s core businesses and include a live Q&A session. This is the first time Precipio will incorporate a dedicated moderated Q&A into its quarterly update. Investors can submit questions in advance to investors@precipiodx.com or join the call by dialing 646.307.1865. A replay will be available on Pre...
05-06 21:00
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced the FDA acceptance of its NDA for lorundrostat to treat hypertension, with a PDUFA target date of December 22, 2026. The company highlighted its strong progress in advancing lorundrostat, supported by five positive clinical trials demonstrating significant blood pressure reduction and favorable safety. Financially, the company reported $646.1 million in cash and investments as of March 2026, with reduced R&D expen...
05-06 20:05
UPDATE 1-Venezuela's bonds rally as US authorises debt restructuring advisors
UPDATE 1-Venezuela's bonds rally as US authorises debt restructuring advisors Adds detail throughout, comments Bonds rally as U.S. authorises Venezuela to hire advisors Venezuela's external debt amounts to $150-$170 billion Restructuring could be largest ever seen By Marc Jones LONDON, May 6 (Reuter
05-06 18:52
BUZZ-Coty falls after flagging sales hit from Middle East conflict
BUZZ-Coty falls after flagging sales hit from Middle East conflict ** Shares of CoverGirl parent Coty COTY.N fall nearly 2% to $2.51 premarket ** Co on Tuesday flagged a hit to sales from the conflict in the Middle East, even as it leaned on cost-cutting to reinstate its annual profit target ** J.P.
05-06 16:41
Vishay Intertechnology ESD Protection Diode Passes IEEE 10BASE-T1S Compliance Tests
Vishay's VETH100A1DD1 ESD protection diode has passed IEEE 10BASE-T1S compliance testing, meeting all three OPEN Alliance EMC Test Specifications. It supports 10BASE-T1S, 100BASE-T1, and 1000BASE-T1 applications, offering low capacitance (<1 pF) for signal integrity in automotive Ethernet systems. This makes it suitable for multidrop bus and high-speed point-to-point links, providing a versatile ESD protection solution for automotive designs.
05-06 15:00
CSX, CPKC upgrade Southeast Mexico Express with dedicated train, faster transit times
CSX and CPKC have upgraded their Southeast Mexico Express (SMX) service, offering faster transit times and expanded origin and destination options for customers connecting U.S. Southeast markets like Atlanta and Florida with Texas and Mexico, including Dallas and Monterrey. Transit times have improved by up to 45%, with direct connectivity and enhanced infrastructure supporting more efficient and reliable service. The collaboration between the tw...
05-06 13:00
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong Q1 2026 results with global revenue of $205 million, including $195 million from BRIUMVI in the U.S. The company raised its full-year 2026 revenue target to $925 million, with U.S. BRIUMVI net product revenue expected to reach $885-900 million. Q2 2026 BRIUMVI U.S. net product revenue is projected at $220 million. BRIUMVI continues to show strong demand and patient growth, with ongoing clinical developments for sub...
05-06 11:00
